Professor Ian Wicks

		Qualifications:		MBBS, FRACP, PhD.
		Position:		Director AFV Centre for Rheumatic Diseases
		Location:		AFV Centre for Rheumatic Diseases
		Postal Address:		AFV Centre for Rheumatic Diseases C/- The University of Melbourne Department of Medicine (RMH/WH) Royal Melbourne Hospital 4th Floor Clinical Sciences Building Parkville, Melbourne, Victoria, Australia 3050
		Telephone:		+61-3 9342 7634
		Fax:		+61-3 9342 7632
		Email:		Ian.Wicks@mh.org.au

Background

Professor Wicks is a clinician-scientist who studied medicine at The University of Sydney and undertook clinical training at Sydney Hospital and then Prince of Wales/Prince Henry Hospitals. After completing basic physician training he specialised in Rheumatology. He was awarded an NHMRC Post Graduate Scholarship to undertake a PhD at the Walter & Eliza Hall Institute in Melbourne, resulting in the cloning of a novel human receptor tyrosine kinase, hek (now known as EphA3). During his PhD he received an award from the International Union Against Cancer to work at Harvard University on gene cloning techniques. He was subsequently awarded an NHMRC Neil Hamilton Fairlie Post Doctoral Fellowship to work at the University of California, San Diego on gene therapy in autoimmune disease models. In 1998 he was appointed Professor/Director of Rheumatology at Royal Melbourne Hospital and Director of the AFV Centre for Rheumatic Diseases, in conjunction with a continuing appointment as Head of the Reid Rheumatology Laboratory at the Walter & Eliza Hall Institute. In 2001, he was appointed an NHMRC Clinical Practitioner Fellow and this appointment was renewed in 2006.

Research Interests

The pathogenesis and management of autoimmune, inflammatory disorders, in particular rheumatoid arthritis and complications thereof (such as accelerated atherosclerosis). As Director of the CRD, Professor Wicks has promoted a research agenda tackling broader issues in the rheumatic diseases, including improving patient education and prioritisation for joint replacement surgery.

Biography:

Publications 2001 -

1. Molecular and cellular mediators of IL-1 dependent, acute inflammatory arthritis. Lawlor KE, Campbell IK, O'Donnell K, Wu L, Wicks IP. Arthritis & Rheumatism 2001;44:442-450
2. VCAM-1 (CD106): a multi-facetted regulator of joint inflammation. Carter R & Wicks IP. Arthritis & Rheumatism 2001;44:985-994
3. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. Campbell IK, O'Donnell K, Lawlor K & Wicks IP. Journal of Clinical Investigation 2001;107:1519-1527
4. Characterisation of a human synovial cell antigen: VCAM-1 and inflammatory arthritis. Carter RA, O'Donnell K, Sachthep S, Cicuttini F, Boyd A and Wicks IP. Immunology and Cell Biology 2001;79:419-428
5. Defective gp-130 mediated signal transduction and activator of signal transduction (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration and failure of uterine implantation. Ernst M, Inglese M, Waring P, Campbell I, Bao S, Clay FJ, Alexander WS, Wicks IP, Tarlinton DM, Novak U, Heath JK, Dunn AR. Journal of Experimental Medicine 2001:194;189-204
6. Vascular cell adhesion molecule-1 (VCAM-1) blockade in collagen-induced arthritis reduces joint involvement and alters B cell trafficking. Carter RA, Campbell IK, O’Donnell K, Wicks IP. Clin Exp Immunol. 2002 Apr;128(1):44-51.
7. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Van Doornum S, McColl G, Wicks IP. Arthritis Rheum. 2002 Apr;46(4):862-73.
8. Gross abdominal lymphadenopathy in sarcoidosis. Ostor A, Moran H, Wicks IP. Internal Medicine Journal 2002; 32:422-424..
9. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Moore J, Brooks P, Milliken S, Biggs J, Ma D, Handel M, Cannell P, Will R, Rule S, Joske D, Langlands B, Taylor K, O'Callaghan J, Szer J, Wicks IP, McColl G, Passeullo F, Snowden J. Arthritis Rheum. 2002 Sep;46(9):2301-9.
10. An ethyl-nitrosourea-induced point mutation in Phex causes exon skipping, X-linked hypophosphatemia and rickets. Carpinelli M, Wicks IP, Sims NA, O’Donnell K, Hanzinikolas K, Burt RA, Foote SJ, Bahlo M, Alexander WS, Hilton DJ. American Journal of Pathology 2002;161:1925-1933.
11. Screening for Atherosclerosis in Rheumatoid Arthritis: Comparison of Two In-Vivo Tests of Vascular Function. Van Doornum S, Jenkins A, McColl G & Wicks IP. Arthritis & Rheumatism 2003;48:72-80.
12. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Wong M, Toh L, Wilson A, Rowley K, Karschimkus C, prior D, Romas E, Clemens L, Dragivec G, Harianto H, Wicks IP, McColl G, Best J & Jenkins A. Arthritis & Rheumatism 2003;48:81-89.
13. The role of the IL-6 family of cytokines in inflammatory arthritis and bone turnover. Wong P, Campbell IK, Egan PJ, Ernst M & Wicks IP. Arthritis & Rheum 2003;48:1177-1189.
14. SOCS-1 regulates acute inflammatory arthritis and T cell activation. Egan P, Lawlor K, Alexander W & Wicks IP. J Clin Invest 2003;111:915-.
15. Molecular targets in immune-mediated diseases: the case of TNF in RA. Campbell IK, Roberts LJ, Wicks IP. Immunol. Cell Biol. 2003;81:354-366.
16. Ventricular thombi in anti-phospholipid antibody syndrome. Lim E, Wicks IP, Roberts LJ. Internal Medicine Journal 2004;34:135-7.
17. Arthritis self-management programs in Australia. Osborne RO, Spinks J & Wicks IP. MJA 2004;180:S23-6.
18. Critical role for granulocyte colony stimulating factor in inflammatory arthritis. Lawlor KE, Campbell IK, Metcalf, D, O’Donnell K, van Nieuwenhuijze A, Roberts AW & Wicks IP. Proc Nat Acad Sciences, USA 2004;101:11398-11403.
19. Effect of atorvastatin on vascular function in rheumatoid arthritis. Van Doornum S, McColl G & Wicks IP. Annals of Rheumatic Diseases 2004;63:1571-1575.
20. Endogenous IL-11 is pro-inflammatory in acute methylated bovine serum albumin/IL-1 induced arthritis. Wong PK, Campbell IK, Robb L & Wicks IP. Cytokine 2005;29:72-76.
21. TNF Antagonists Improve Disease Activity But Not Arterial Stiffness in RA. Van Doornum S, McColl J & Wicks IP. Rheumatology (Oxford) 2005; Aug 2.
22. Severely compromised quality of life in women and those of lower socioeconomic status waiting for joint replacement  surgery. Ackerman I, Graves S, Bennell K, Wicks IP, Osborne RH. Arthritis Care & Research 2005;53:653-658.
23. Development of spontaneous multi-system autoimmune disease and hypersensitivity to antibody induced inflammation in FcgRIIa transgenic mice.
24. Tan Sardjono C, Mottram PL, Van de Velde NC, Powell MS, Power D, Slocombe RF, Wicks IP, Campbell IK et al. Arthritis & Rheumatism 2005;52:32220-3229.
25. Sustained remission, possibly cure, of seronegative arthritis after high dose chemotherapy and syngeneic hematopoietic stem cell transplantation. McColl G, Szer J & Wicks IP. Arthritis & Rheumatism 2005;52:3322.
26. Acute CD4+ T lymphocyte dependent IL-1 driven arthritis selectively requires IL-2 and IL-4, joint macrophages, GM-CSF, IL-6 and LIF. Lawlor KE, Wong PKK, Campbell IK, Van Rooijen N, Wicks IP. Arthritis & Rheumatism 2005;52:3749-3754.
27. Interleukin-6 modulates production of T-lymphocyte derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Wong PKK, Quinn JMW, Sims NA, Nieuwenhuijze A, Campbell IK, Wicks IP. Arthritis & Rheumatism 2006;54:158-168.
28. Reducing the cardiovascular burden in rheumatoid arthritis. Van Doornum S, Jennings G, Wicks IP. Medical Journal of Australia 2006;184:287-290.
29. Intrasplenic precursors of steady-state dendritic cells that are distinct from monocytes. Nalik S, Metcalf D, Nieuwenhuijze AM, Wicks IP, Shortman K. Nature Immunology 2006;7(6):663-671.
30. Suppressor of cytokine signaling 3 (SOCS-3) negatively regulates innate and adaptive immune mechanisms in acute, IL-1 dependent inflammatory arthritis. Wong PKK, Egan PJ, Croker BA, Alexander WS, O’Donnell K, Roberts AW, Wicks IP. Journal of Clinical Investigation 2006;116(6):1571-1581.
31. Granulocyte colony stimulating factor and neutrophils – forgotten mediators of inflammatory diseases. Eyles JL, Roberts AW, Metcalf D, Wicks IP. Nature Clinical Practice Rheumatology 2006;2(9);1-11. 

Appointments:

Professor/Director Rheumatology Unit, Royal Melbourne Hospital,

Director, Centre for Rheumatic Diseases, University of Melbourne &

Head, Reid Rheumatology Laboratory, Division of Autoimmune Diseases & Transplantation, Walter & Eliza Hall Institute of Medical Research